Mendus AB (publ)

Mendus AB (publ)verified

IMMU.ST

Price:

$5.07

Market Cap:

$257.32M

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company w...[Read more]

Industry

Biotechnology

IPO Date

2013-04-22

Stock Exchange

STO

Ticker

IMMU.ST

The PE Ratio as of December 2025 (TTM) for Mendus AB (publ) (IMMU.ST) is -2.50

According to Mendus AB (publ)’s latest financial reports and current stock price. The company's current PE Ratio is -2.50. This represents a change of -31.22% compared to the average of -3.63 of the last 4 quarters.

Mendus AB (publ) (IMMU.ST) Historical PE Ratio (quarterly & annually)

How has IMMU.ST PE Ratio performed in the past?

The mean historical PE Ratio of Mendus AB (publ) over the last ten years is -99.13. The current -2.50 PE Ratio has changed 152.20% with respect to the historical average. Over the past ten years (40 quarters), IMMU.ST's PE Ratio was at its highest in in the December 2023 quarter at -2.33. The PE Ratio was at its lowest in in the December 2020 quarter at -692.85.

Quarterly (TTM)
Annual

Average

-99.13

Median

-104.96

Minimum

-219.73

Maximum

-2.38

Mendus AB (publ) (IMMU.ST) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Mendus AB (publ) PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 84.12%

Maximum Annual PE Ratio = -2.38

Minimum Annual Increase = -96.88%

Minimum Annual PE Ratio = -219.73

Quarterly (TTM)
Annual
YearPE RatioChange
2024-2.9524.28%
2023-2.38-96.88%
2022-76.17-39.18%
2021-125.23-5.44%
2020-132.446.46%
2019-124.4145.48%
2018-85.5284.12%
2017-46.45-73.61%
2016-175.98-19.91%
2016-219.73-21.39%

Mendus AB (publ) (IMMU.ST) Average PE Ratio

How has IMMU.ST PE Ratio performed in the past?

The current PE Ratio of Mendus AB (publ) (IMMU.ST) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-27.17

5-year avg

-67.83

10-year avg

-99.13

Mendus AB (publ) (IMMU.ST) PE Ratio vs. Peers

How is IMMU.ST’s PE Ratio compared to its peers?

Mendus AB (publ)’s PE Ratio is greater than Ascelia Pharma AB (publ) (-3.99), greater than Intervacc AB (publ) (-4.77), greater than Magle Chemoswed Holding AB (publ) (-13.28), greater than Xintela AB (publ) (-4.20), less than Moberg Pharma AB (publ) (-1.66), greater than Elicera Therapeutics AB (publ) (-20.43), less than Karolinska Development AB (publ) (-0.92), greater than Lipum AB (publ) (-4.10), greater than Corline Biomedical AB (-17.15), greater than Isofol Medical AB (publ) (-3.37),

Build a custom stock screener for Mendus AB (publ) (IMMU.ST) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mendus AB (publ) using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Mendus AB (publ) (IMMU.ST) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Mendus AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Mendus AB (publ)'s PE Ratio?

How is the PE Ratio calculated for Mendus AB (publ) (IMMU.ST)?

What is the highest PE Ratio for Mendus AB (publ) (IMMU.ST)?

What is the 3-year average PE Ratio for Mendus AB (publ) (IMMU.ST)?

What is the 5-year average PE Ratio for Mendus AB (publ) (IMMU.ST)?

How does the current PE Ratio for Mendus AB (publ) (IMMU.ST) compare to its historical average?